Our dedicated executive team propels us toward innovation, aiming to be at the forefront of Diabetes Management.
Board of Directors
Patrick Smith, President and Founder
Experienced in healthcare operations, clinical scale up, patient experience and technology.
Dr. Robert Bouvier, Director, Secretary & Treasurer; Chair, Clinical Research Advisory Committee
Internal Medicine | 41 Years of Experience
Dr. Bouvier brings more than four decades of internal medicine experience in helping patients manage metabolic health conditions. He chairs the committee that advises TPHI’s board on clinical research.
His internal medicine background provides valuable perspective for patients seeking a more comprehensive approach to hydration, recovery, metabolic wellness, preventive health, peptide-informed wellness planning, longevity support, regenerative wellness education, and biologics review where clinically appropriate.
Management
Dr. Ky Hong Le M.D., Medical Director
Family Medicine & Hospitalist-Informed Care | 24 Years of Experience
Dr. Le brings more than two decades of family medicine, hospital medicine, and patient-centered clinical experience to the institute. As Medical Director he directs clinical care across TPHI’s programs, including the Focused Insulin Therapy protocol and the Institute’s low-cost treatments for metabolic dysregulation and diabetes complications.
His family medicine and hospitalist-informed background helps support patients seeking hydration therapy, immune support, recovery care, metabolic optimization, preventive health, peptide-informed wellness planning, longevity support, regenerative wellness education, and biologics review where clinically appropriate.
Principal Investigators
Jonathan Lakey, PhD, MSM, Scientific Advisor; Principal Investigator (designate), FIT Study
For more than two decades, he has been a global research leader in the fields of diabetes, islet and stem cell transplantation, exosomes, cellular metabolism and signaling, immunology, cellular encapsulation, in vivo biomaterial and bio-implantable polymers.
Dr. Lakey guided the clinical and scientific development of Focused Insulin Therapy and the design of TPHI’s IRB study framework. He supports the Institute on an ad hoc basis and will serve as principal investigator once the study is funded.